Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 1;2(6):730-6.
doi: 10.1001/jamaoncol.2015.5941.

BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer

Shoshana M Rosenberg  1 , Kathryn J Ruddy  2 , Rulla M Tamimi  3 , Shari Gelber  4 , Lidia Schapira  5 , Steven Come  6 , Virginia F Borges  7 , Bryce Larsen  1 , Judy E Garber  1 , Ann H Partridge  1
Affiliations

BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer

Shoshana M Rosenberg et al. JAMA Oncol. .

Abstract

Importance: BRCA testing is recommended for young women diagnosed as having breast cancer, but little is known about decisions surrounding testing and how results may influence treatment decisions in young patients.

Objectives: To describe the use of BRCA testing and to evaluate how concerns about genetic risk and use of genetic information affect subsequent treatment decisions in young women with breast cancer.

Design, setting, and participants: Cross-sectional analysis of data collected following the opening of the study to accrual from October 10, 2006, through December 31, 2014, as part of the Helping Ourselves, Helping Others: Young Women's Breast Cancer Study, an ongoing prospective cohort study. Study participants included 897 women aged 40 years and younger at breast cancer diagnosis from 11 academic and community medical centers.

Main outcomes and measures: Frequency and trends in the use of BRCA testing and how genetic information is used to make treatment decisions among women who test positive vs negative for a BRCA mutation.

Results: A total of 780 (87.0%) of 897 women reported BRCA testing by 1 year after breast cancer diagnosis (mean age at diagnosis, 35.3 vs 36.9 years for untested women; P < .001), with the frequency of testing increasing among women diagnosed from August 1, 2006, through December 31, 2013. Of 39 women who were diagnosed as having breast cancer in 2006, 30 (76.9%) reported testing. In 2007, a slightly lower percentage of women (87 of 124 [70.2%]) reported testing; however, the proportion tested increased each subsequent year, with 141 (96.6%) of 146 and 123 (95.3%) of 129 women diagnosed as having breast cancer in 2012 and 2013, respectively, reporting BRCA testing (P < .001). Among untested women, 37 (31.6%) of 117 did not report discussion of the possibility that they might have a mutation with a physician and/or genetic counselor, and 43 (36.8%) of 117 were thinking of testing in the future. A total of 248 (29.8%) of 831 women said that knowledge or concern about genetic risk influenced treatment decisions; among these women, 76 (86.4%) of 88 mutation carriers and 82 (51.2%) of 160 noncarriers chose bilateral mastectomy (P < .001). Fewer women reported that systemic treatment decisions were influenced by genetic risk concern.

Conclusions and relevance: Rates of BRCA1 and BRCA2 mutation testing are increasing in young women with breast cancer. Given that knowledge and concern about genetic risk influence surgical decisions and may affect systemic therapy trial eligibility, all young women with breast cancer should be counseled and offered genetic testing, consistent with the National Comprehensive Cancer Network guidelines.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest/Disclosures: Dr. Garber receives research funding from Myriad Genetics and Ambry Genetics and is a consultant for Pfizer and Sequenom. No other conflicts are reported.

Figures

Figure 1
Figure 1
Study flow chart of study participants included in analytic sample YWS – Young Women's Breast Cancer Study
Figure 2
Figure 2
Trends in BRCA testing in the YWS cohort (N=897) YWS – Young Women's Breast Cancer Study
See this image and copyright information in PMC

Comment in

References

    1. Bleyer A, Barr R. Cancer in young adults 20 to 39 years of age: overview. Semin Oncol. 2009;36(3):194–206. - PubMed
    1. National Comprehensive Cancer Network (NCCN) Clinical practices guidelines in oncology: Genetic/familial high-risk assessment: Breast and ovarian v.1.2014. [Accessed August 4, 2014];
    1. Malone KE, Begg CB, Haile RW, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010;28(14):2404–2410. - PMC - PubMed
    1. Brown KL, Hutchison R, Zinberg RE, McGovern MM. Referral and experience with genetic testing among women with early onset breast cancer. Genet Test. 2005;9(4):301–305. - PubMed
    1. Ruddy KJ, Gelber S, Shin J, et al. Genetic testing in young women with breast cancer: results from a Web-based survey. Ann Oncol. 2010;21(4):741–747. - PubMed